About
Professional Summary
See-Hyoung Park currently works as principle investigator in Seoul National University, Graduate School of Convergence Science and Technology, Korea (South). He received his Ph.D. degree in 2009 from the Graduate Group of Comparative Pathology (GGCP) at University of California in Davis, where he received the Block Grant from GGCP that covered part of his tuition and fees. His prior work experience includes senior scientific researcher at Mogam Biotechnology Research Institute, one of the renowned Biotechnology Institutes and Dr. Mickey Hus laboratory in the Division of Gynecologic Oncology at Stanford University Medical Center and Stanford Cancer Institute as a Postdoctoral scholar. Dr. Park demonstrated the highest degree of enthusiasm in pursuing anti-cancer drug discovery using chemical genomics since he joined Stanford University, and he has identified a number of novel anticancer compounds based on his innovative drug-discovery strategies.
Education
Academic Background
Editorial Services
Editorial & Publishing Roles
Editorial Board Member
Jul 2019 — Present
Serving as Editorial Board Member for Biotechnology.
Editorial Board Member
Jul 2019 — Present
Serving as Editorial Board Member for International Journal of Cancer Research.
Publications (18)
Selected Scholarly Contributions
CK2α phosphorylates DBC1 and involves in the progression of gastric carcinoma and predicts poor survival of gastric carcinoma patients.
Bae, J.S., S.H. Park, K.M. Kim, K.S. Kwon and C.Y. Kim et al.,
Int. J. Cancer,
| Journal Article
See Hyoung Park
2015
Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53.
Park, S.H., J.H. Lee, J.S. Berek and M.C.T. Hu,
Int. J. Oncol.,
| Journal Article
See Hyoung Park
2014
Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer.
Liu, R., H.I. Wettersten, S.H. Park and R.H. Weiss,
Future Med. Chem.,
| Journal Article
See Hyoung Park
2013
Discovery of targeting ligands for breast cancer cells using the one-bead one-compound combinatorial method.
Yao, N., W. Xiao, X. Wang, J. Marik, S.H. Park, Y. Takada and K.S. Lam,
J. Med. Chem.,
| Journal Article
See Hyoung Park
2009
Disparate effects of roscovitine on renal tubular epithelial cell apoptosis and senescence: Implications for ADPKD.
Park, J.Y., S.H. Park and R.H. Weiss,
Am. J. Nephrol.,
| Journal Article
See Hyoung Park
2009
Sorafenib has soluble epoxide hydrolase inhibitory activity which contributes to its effect profile in vivo.
Liu, J.Y., S.H. Park, C. Morisseau, S.H. Hwang, B.D. Hammock and R.H. Weiss,
Mol. Cancer Therap.,
| Journal Article
See Hyoung Park
2009
Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA-damaging chemotherapy associated with enhancement of phospho-p53.
Park, S.H., J.Y. Park and R.H. Weiss,
J. Urol.,
| Journal Article
See Hyoung Park
2008
High throughput combinatorial screening of small molecules to identify attenuator of p21 as potential novel therapy of renal cell carcinoma.
Park, S.H., X. Wang, R. Liu, K.S. Lam and R.H. Weiss,
Cancer Biol. Ther.,
| Journal Article
See Hyoung Park
2008
Structure activity relationship of the series of non-peptide small antagonists for p56lck sh2 domain.
Park, S.H., H.S. Oh, M.A. Kang, H. Cho, J.B. Prasad, J. Won and K.H. Lee,
Bioorg. Med. Chem.,
| Journal Article
See Hyoung Park
2007
Crystallization of antiangiogenic kringle V derived from human apolipoprotein A: Crystallization applied to purification and formulation.
Kang, K.Y., J.H. Park, I.H. Lim, S.G. Kim and S.H. Park et al.,
Biosci. Biotechnol. Biochem.,
| Journal Article
See Hyoung Park
2006
Development of novel small chemical inhibitors for Lck SH2 domain with in vitro T-cell inhibitory activity.
Park, S.H., M.A. Kang, H.S. Shim, H. Cho, J. Won and K.H. Lee,
Bull. Korean Chem. Soc.,
| Journal Article
See Hyoung Park
2006
Extended operation of a pressurized 75-L bioreactor for shLkn-1 production by Pichia pastoris using dissolved oxygen profile control.
Woo, S.H., S.H. Park, H.K. Lim and K.H. Jung,
J. Microbiol. Biotechnol.,
| Journal Article
See Hyoung Park
2005
The relationship between the pY+3 amino acid in the phosphopeptide ligands and the binding affinity for various SH2 domains.
Lee, K.H. and S.H. Park,
Protein Peptide Lett.,
| Journal Article
See Hyoung Park
2004
Non-phosphopeptide inhibitor for Lck SH2 domain: Solid-phase synthesis and structure activity relationship of rosmarinic acid analogs.
Kang, S.H., S.H. Park, H.S. Shim and K.H. Lee,
Bull. Korean Chem. Soc.,
| Journal Article
See Hyoung Park
2003
Design and synthesis of small chemical inhibitors containing different scaffolds for lck SH2 domain.
Park, S.H., S.H. Kang, S.H. Lim, H.S. Oh and K.H. Lee,
Bioorg. Med. Chem. Lett.,
| Journal Article
See Hyoung Park
2003
Rosmarinic acid inhibits TCR-induced T cell activation and proliferation in an Lck-dependent manner.
Won, J., Y.G. Hur, E.M. Hur, S.H. Park and M.A. Kang et al.,
Eur. J. Immunol.,
| Journal Article
See Hyoung Park
2003
Design and characterization of non-phosphopeptide inhibitors for src family SH2 domains.
Park, S.H., J. Won and K.H. Lee,
Bioorg. Med. Chem. Lett.,
| Journal Article
See Hyoung Park
2002
Studies on xanthine oxidase inhibitor produced from Aspergilus SP. F184.
Park, S.H., S.W. Yun, J.M. Park, S.H. Ok, J.H. Yu and D.H. Bai ,
Korean J. Microbiol. Biotechnol.,
| Journal Article
See Hyoung Park
2000
